FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

5-2020

Published In/Presented At

• Toni K. Choueiri et al.,

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).. JCO 38, 5007-5007(2020).

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article